Gain Therapeutics Inc. (GANX)
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinsons Disease
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinsons Disease
Digital Realty Announces Secondary Offering of Common Stock by Blackstone
Identiv Investor Alert: Kahn Swick & Foti, LLC Investigates Identiv, Inc. - INVE
TFI International to Release Second Quarter 2026 Results
Ampco-Pittsburgh Corporation Joins US small-cap Russell 2000® Index
XPO Schedules Second Quarter 2026 Earnings Conference Call for Thursday, July 30, 2026
PACS Group to Acquire Operations of 34 Facilities Across Texas, Montana, New Mexico, North Dakota, South Dakota, and Utah
Nasdaq to Hold Second Quarter 2026 Investor Conference Call
Frontdoor Names Finance and Real Estate Executive Hilla Sferruzza to Board of Directors
Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant un bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité